FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105162502> ?p ?o ?g. }

• W2105162502 endingPage "689" @default.
• W2105162502 startingPage "681" @default.
• W2105162502 abstract "Previous studies have identified interleukin 6 (IL-6) as an important cytokine with prognostic significance in ovarian cancer. Activation of the IL-6-Stat3 pathway contributes to tumor cell growth, survival and drug resistance in several cancers, including ovarian cancer. To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of CDDO-Me, a synthetic triterpenoid, to inhibit IL-6 secretion, Stat3 phosphorylation, Stat3 nuclear translocation and paclitaxel sensitivity in several cell line model systems. These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation. Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3. This inhibition of the IL-6-Stat3 pathway correlated with suppression of the anti-apoptotic Stat3 target genes Bcl-XL, survivin, and Mcl-1, and with apoptosis induction as measured by monitoring PARP and its cleavage product, as well as by quantitative measurement of the apoptosis-associated CK18Asp396. Furthermore, CDDO-Me increases the cytotoxic effects of paclitaxel in the paclitaxel-resistant ovarian cancer cell line OVCAR8TR (2 to 5-fold) and of cisplatin in the cisplatin-resistant ovarian cancer cell line A2780cp70 (2 to 4-fold). Our data confirm that CDDO-Me interrupts the signaling of multiple kinases involved in the IL-6-Stat3 and Src signaling pathways. Inhibition is likely achieved through multiple points within these pathways. In a model system of established acquired drug resistance, CCDO-Me is effective at partially reversing the drug-resistance phenotype." @default.
• W2105162502 created "2016-06-24" @default.
• W2105162502 creator A5000311133 @default.
• W2105162502 creator A5036176260 @default.
• W2105162502 creator A5038077156 @default.
• W2105162502 creator A5065734287 @default.
• W2105162502 creator A5082130171 @default.
• W2105162502 creator A5082326728 @default.
• W2105162502 date "2008-06-28" @default.
• W2105162502 modified "2023-10-01" @default.
• W2105162502 title "CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells" @default.
• W2105162502 cites W1520422891 @default.
• W2105162502 cites W1548640328 @default.
• W2105162502 cites W1759028523 @default.
• W2105162502 cites W1967521794 @default.
• W2105162502 cites W1968365367 @default.
• W2105162502 cites W1978166647 @default.
• W2105162502 cites W1980494624 @default.
• W2105162502 cites W1987669162 @default.
• W2105162502 cites W2000178617 @default.
• W2105162502 cites W2001724432 @default.
• W2105162502 cites W2002930632 @default.
• W2105162502 cites W2007421939 @default.
• W2105162502 cites W2022897778 @default.
• W2105162502 cites W2039870307 @default.
• W2105162502 cites W2058727371 @default.
• W2105162502 cites W2083802827 @default.
• W2105162502 cites W2095818256 @default.
• W2105162502 cites W2107436374 @default.
• W2105162502 cites W2119643998 @default.
• W2105162502 cites W2122884740 @default.
• W2105162502 cites W2125933228 @default.
• W2105162502 cites W2126150441 @default.
• W2105162502 cites W2159118796 @default.
• W2105162502 cites W2160382180 @default.
• W2105162502 cites W2163820705 @default.
• W2105162502 cites W2170090299 @default.
• W2105162502 cites W2783142245 @default.
• W2105162502 doi "https://doi.org/10.1007/s00280-008-0785-8" @default.
• W2105162502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2875930" @default.
• W2105162502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18587580" @default.
• W2105162502 hasPublicationYear "2008" @default.
• W2105162502 type Work @default.
• W2105162502 sameAs 2105162502 @default.
• W2105162502 citedByCount "62" @default.
• W2105162502 countsByYear W21051625022012 @default.
• W2105162502 countsByYear W21051625022013 @default.
• W2105162502 countsByYear W21051625022014 @default.
• W2105162502 countsByYear W21051625022015 @default.
• W2105162502 countsByYear W21051625022016 @default.
• W2105162502 countsByYear W21051625022017 @default.
• W2105162502 countsByYear W21051625022018 @default.
• W2105162502 countsByYear W21051625022019 @default.
• W2105162502 countsByYear W21051625022020 @default.
• W2105162502 countsByYear W21051625022021 @default.
• W2105162502 countsByYear W21051625022022 @default.
• W2105162502 countsByYear W21051625022023 @default.
• W2105162502 crossrefType "journal-article" @default.
• W2105162502 hasAuthorship W2105162502A5000311133 @default.
• W2105162502 hasAuthorship W2105162502A5036176260 @default.
• W2105162502 hasAuthorship W2105162502A5038077156 @default.
• W2105162502 hasAuthorship W2105162502A5065734287 @default.
• W2105162502 hasAuthorship W2105162502A5082130171 @default.
• W2105162502 hasAuthorship W2105162502A5082326728 @default.
• W2105162502 hasBestOaLocation W21051625022 @default.
• W2105162502 hasConcept C121608353 @default.
• W2105162502 hasConcept C190283241 @default.
• W2105162502 hasConcept C2775975398 @default.
• W2105162502 hasConcept C2776694085 @default.
• W2105162502 hasConcept C2777292972 @default.
• W2105162502 hasConcept C2778239845 @default.
• W2105162502 hasConcept C2778923194 @default.
• W2105162502 hasConcept C2780427987 @default.
• W2105162502 hasConcept C502942594 @default.
• W2105162502 hasConcept C54355233 @default.
• W2105162502 hasConcept C55493867 @default.
• W2105162502 hasConcept C62478195 @default.
• W2105162502 hasConcept C86803240 @default.
• W2105162502 hasConcept C95444343 @default.
• W2105162502 hasConceptScore W2105162502C121608353 @default.
• W2105162502 hasConceptScore W2105162502C190283241 @default.
• W2105162502 hasConceptScore W2105162502C2775975398 @default.
• W2105162502 hasConceptScore W2105162502C2776694085 @default.
• W2105162502 hasConceptScore W2105162502C2777292972 @default.
• W2105162502 hasConceptScore W2105162502C2778239845 @default.
• W2105162502 hasConceptScore W2105162502C2778923194 @default.
• W2105162502 hasConceptScore W2105162502C2780427987 @default.
• W2105162502 hasConceptScore W2105162502C502942594 @default.
• W2105162502 hasConceptScore W2105162502C54355233 @default.
• W2105162502 hasConceptScore W2105162502C55493867 @default.
• W2105162502 hasConceptScore W2105162502C62478195 @default.
• W2105162502 hasConceptScore W2105162502C86803240 @default.
• W2105162502 hasConceptScore W2105162502C95444343 @default.
• W2105162502 hasIssue "4" @default.
• W2105162502 hasLocation W21051625021 @default.
• W2105162502 hasLocation W21051625022 @default.
• W2105162502 hasLocation W21051625023 @default.
• W2105162502 hasLocation W21051625024 @default.

• next